Cutaneous Fibrosis Treatment Market Forecasted to Grow at 5.9% CAGR Through 2034

In 2024, the global cutaneous fibrosis treatment market (皮膚線維症治療市場) is estimated at US$702.2 million, with a projected compound annual growth rate (CAGR) of 5.9% through 2034. By 2034, the market is expected to exceed US$1,243.6 million.Several factors contribute to the increasing demand for cutaneous fibrosis treatment, including a growing number of patients with scleroderma and other disorders like keloid seeking treatment.

Get Free Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9359

Other reasons for the increase in patients requiring cutaneous fibrosis treatment include the number of people admitted with wounds to hospitals and the number of people undergoing radiation therapies. The trends dictate the normalization of appearance-improving treatments for cancer patients. Similarly, people involved in accidents or who received any other type of wound also look to shape up appearances. Thus, the profile of cutaneous fibrosis treatment is rising.

Cutaneous fibrosis treatment is still an evolving medical science. Thus, there is still ignorance about the treatment among the people. The lack of awareness extends to the disorders related to cutaneous fibrosis themselves. The limited number of treatment options is also negatively impacting the market. However, market players invest in Research and Development to develop novel drugs and treatments.

Key Takeaways from the Market Study

The global cutaneous fibrosis treatment market (피부 섬유증 치료 시장) is projected to expand at a CAGR of 5.9% through 2034.
The North America cutaneous fibrosis treatment market is expected to grow at a CAGR of 6.1% from 2024 to 2034.
The cutaneous fibrosis treatment industry is expected to register a CAGR of 6.1% in the United States over the forecast period.
Mexico's cutaneous fibrosis treatment industry is expected to rise at a CAGR of 6.6% through 2034.
Based on indication, the scleroderma segment to lead the market, with an expected share of 68.3% in 2024.
Country-wise Insights

In the market, North America holds a prominent position. The North American market is expected to be valued US$ 249.0 million in 2024, with a 35.5% market share. In North America, the market is anticipated to grow at a robust 6.1% CAGR between 2024 and 2034. The market is anticipated to have increased to US$ 452.0 million throughout the projected period, with a share of 36.4% in North America.

In 2024, Latin America is projected to provide 6.6% of the total, valued at US$ 46 million. The projected CAGR for Latin America is estimated to be 5.8% on average during the forecast period. Latin America's market share is predicted to be 6.5% by 2034, and the region's valuation is projected to reach US$ 81 million.

Key Companies Profiled in This Report

Novartis AG
Pfizer
Sanofi
F. Hoffmann La Roche (Genetech, Inc.)
Boehringer Ingelheim International GmbH
Jubilant Cadista
Horizon Pharma USA, Inc.
Bristol-Myers Squibb Company
Teva Pharmaceuticals
Amgen
Johnson & Johnson Services

New Forms of Treatment and Drugs Take Centre Stage for Market Players

Market players are concentrating on developing innovative forms of treatment. Sales through the online channel are also receiving prominence in company policies. Some prominent companies in the market are Bristol-Myers Squibb Company, Teva Pharmaceuticals, Amgen, and Johnson & Johnson Services.

Some of the recent developments in the market are:

In October 2023, Kyverna Therapeutics' KYV-101 drug was announced to be cleared for investigative use by the FDA.
In a 2021 study, the effects of Rituximab were found to be beneficial in treating systemic sclerosis.

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=9359

Segmentation of Cutaneous Fibrosis Treatment Market (Markt für die Behandlung von Hautfibrose) Research

By Drug Class:

Corticosteroids

Anti-fibrotic Drugs

Immunotherapy

Immunoglobulins

By Route of Administration:

Oral

Injectable

Topical

By Indication:

Keloid

Scleroderma

Radiation-induced Skin Fibrosis

GvHD Associated Cutaneous Fibrosis

By Indication:

Hospital Pharmacies

Retail Pharmacies

Drug Stores

Online Pharmacies

By Region:

North America

Europe

Latin America

East Asia

South Asia & Oceania

Middle East & Africa

Contact:

US Sales Office

11140 Rockville Pike

Suite 400 Rockville, MD 20852

United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D)

Sales Team: sales@factmr.com

About Fact.MR :

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.